APOE and the Association of Fatty Acids With the Risk of Stroke, Coronary Heart Disease, and Mortality - PubMed
. 2018 Dec;49(12):2822-2829.
doi: 10.1161/STROKEAHA.118.022132.
Claudia L Satizabal 1 2 3 , Kendra L Davis-Plourde 2 5 , Barbara Voetsch 6 , Hugo J Aparicio 1 2 , Matthew P Pase 1 2 7 8 , José Rafael Romero 1 2 , Catherine Helmer 4 , Ramachandran S Vasan 9 2 10 , Carlos S Kase 1 11 , Stéphanie Debette 4 12 , Alexa S Beiser 1 2 5 , Sudha Seshadri 1 2 3
Affiliations
- PMID: 30571417
- PMCID: PMC6310220
- DOI: 10.1161/STROKEAHA.118.022132
APOE and the Association of Fatty Acids With the Risk of Stroke, Coronary Heart Disease, and Mortality
Claudia L Satizabal et al. Stroke. 2018 Dec.
Abstract
Background and Purpose- The role of dietary fat on cardiovascular health and mortality remains under debate. Because the APOE is central to the transport and metabolism of lipids, we examined associations between plasma fatty acids and the risk of stroke, coronary heart disease, and mortality by APOE-ε4 genotype. Methods- We included 943 FHS (Framingham Heart Study) and 1406 3C (Three-City) Bordeaux Study participants. Plasma docosahexaenoic, linoleic, arachidonic, and palmitic fatty acids were measured at baseline by gas chromatography. All-cause stroke, ischemic stroke, coronary heart disease, and all-cause mortality events were identified prospectively using standardized protocols. Each cohort used Cox models to separately relate fatty acid levels to the risk of developing each event during ≤10 years of follow-up adjusting for potential confounders and stratifying by APOE genotype (ε4 carriers versus noncarriers). We then meta-analyzed summary statistics using random-effects models. Results- On average, participants had a mean age of 74 years, 61% were women, and 21% (n=483) were APOE-ε4 carriers. Meta-analysis results showed that, only among APOE-ε4 carriers, every SD unit increase in linoleic acid was associated with a reduced risk of all-cause stroke (hazard ratio [HR], 0.54 [95% CI, 0.38-0.78]), ischemic stroke (HR, 0.48 [95% CI, 0.33-0.71]), and all-cause mortality (HR, 0.70 [95% CI, 0.57-0.85]). In contrast, every SD unit increase in palmitic acid was related to an increased risk of all-cause stroke (HR, 1.58 [95% CI, 1.16-2.17]), ischemic stroke (HR, 1.76 [95% CI, 1.26-2.45]), and coronary heart disease (HR, 1.48 [95% CI, 1.09-2.01]), also in APOE-ε4 carriers only. Results for docosahexaenoic acid and arachidonic acid were heterogeneous between cohorts. Conclusions- These exploratory results suggest that APOE-ε4 carriers may be more susceptible to the beneficial or adverse impact of fatty acids on cardiovascular disease and mortality. In this subgroup, higher linoleic acid was protective for stroke and mortality, whereas palmitic acid was a risk factor for stroke and coronary heart disease. The mechanisms underlying these novel findings warrant further investigation.
Keywords: apolipoproteins E; cardiovascular diseases; humans; lipids; mortality.
Figures

Models are adjusted for age, sex, systolic blood pressure, antihypertensive medications, body mass index, smoking, diabetes mellitus, and atrial fibrillation DHA=docosahexaenoic acid; E4+ve (blue)=APOE-ε4 carriers; E4-ve (black)=APOE-ε4 non-carriers; CHD=coronary heart disease, DHA levels are log-transformed, I2=Denotes heterogeneity as the estimated proportion total variance, Phet=P-value from test of heterogeneity, *Meta-analysis was not performed due to a deviation from the proportional hazards assumption when modeling arachidonic acid on ischemic stroke risk among APOE-ε4 carriers from 3C-Bordeaux, †Meta-analysis estimates are not presented due to significant heterogeneity (Phet<0.05)

Models are adjusted for age, sex, systolic blood pressure, antihypertensive medications, body mass index, smoking, diabetes mellitus, and atrial fibrillation, DHA=docosahexaenoic acid; E4+ve (blue)=APOE-ε4 carriers; E4-ve (black)=APOE-ε4 non-carriers; CHD=coronary heart disease, Tertiles are sex-specific I2=Denotes heterogeneity as the estimated proportion total variance, Phet=P-value from test of heterogeneity, *Meta-analysis estimates are not presented due to significant heterogeneity (Phet<0.05), †Meta-analysis was not performed due to a deviation from the proportional hazards assumption when modeling palmitic acid on all-cause mortality risk among APOE-ε4 non-carriers from 3C-Bordeaux
Similar articles
-
Pendlebury ST, Poole D, Burgess A, Duerden J, Rothwell PM; Oxford Vascular Study. Pendlebury ST, et al. Stroke. 2020 Mar;51(3):751-758. doi: 10.1161/STROKEAHA.119.026927. Epub 2020 Feb 18. Stroke. 2020. PMID: 32070224 Free PMC article.
-
Beydoun MA, Beydoun HA, Kaufman JS, An Y, Resnick SM, O'Brien R, Ferrucci L, Zonderman AB. Beydoun MA, et al. J Am Geriatr Soc. 2013 Apr;61(4):525-34. doi: 10.1111/jgs.12156. Epub 2013 Mar 21. J Am Geriatr Soc. 2013. PMID: 23581910 Free PMC article.
-
Satizabal CL, Himali JJ, Beiser AS, Ramachandran V, Melo van Lent D, Himali D, Aparicio HJ, Maillard P, DeCarli CS, Harris WS, Seshadri S. Satizabal CL, et al. Neurology. 2022 Dec 5;99(23):e2572-e2582. doi: 10.1212/WNL.0000000000201296. Neurology. 2022. PMID: 36198518 Free PMC article.
-
Holmes MV, Frikke-Schmidt R, Melis D, Luben R, Asselbergs FW, Boer JM, Cooper J, Palmen J, Horvat P, Engmann J, Li KW, Onland-Moret NC, Hofker MH, Kumari M, Keating BJ, Hubacek JA, Adamkova V, Kubinova R, Bobak M, Khaw KT, Nordestgaard BG, Wareham N, Humphries SE, Langenberg C, Tybjaerg-Hansen A, Talmud PJ. Holmes MV, et al. Atherosclerosis. 2014 Nov;237(1):5-12. doi: 10.1016/j.atherosclerosis.2014.07.038. Epub 2014 Aug 15. Atherosclerosis. 2014. PMID: 25173947 Free PMC article. Review.
-
Chouinard-Watkins R, Plourde M. Chouinard-Watkins R, et al. Nutrients. 2014 Oct 20;6(10):4452-71. doi: 10.3390/nu6104452. Nutrients. 2014. PMID: 25333200 Free PMC article. Review.
Cited by
-
Motawi TK, Sadik NAH, Shaker OG, Ghaleb MMH, Elbaz EM. Motawi TK, et al. Int J Mol Sci. 2024 Jan 10;25(2):842. doi: 10.3390/ijms25020842. Int J Mol Sci. 2024. PMID: 38255915 Free PMC article.
-
Onos KD, Lin PB, Pandey RS, Persohn SA, Burton CP, Miner EW, Eldridge K, Kanyinda JN, Foley KE, Carter GW, Howell GR, Territo PR. Onos KD, et al. Alzheimers Dement. 2024 Jul;20(7):4951-4969. doi: 10.1002/alz.13842. Epub 2024 May 7. Alzheimers Dement. 2024. PMID: 38713704 Free PMC article.
-
Ereqat S, Cauchi S, Eweidat K, Elqadi M, Ghatass M, Sabarneh A, Nasereddin A. Ereqat S, et al. Biomed Rep. 2022 May 27;17(1):61. doi: 10.3892/br.2022.1544. eCollection 2022 Jul. Biomed Rep. 2022. PMID: 35719839 Free PMC article.
-
Genetic Regulatory Networks of Apolipoproteins and Associated Medical Risks.
Basavaraju P, Balasubramani R, Kathiresan DS, Devaraj I, Babu K, Alagarsamy V, Puthamohan VM. Basavaraju P, et al. Front Cardiovasc Med. 2022 Jan 6;8:788852. doi: 10.3389/fcvm.2021.788852. eCollection 2021. Front Cardiovasc Med. 2022. PMID: 35071357 Free PMC article. Review.
-
Jiang W, Li J, Cai Y, Liu W, Chen M, Xu X, Deng M, Sun J, Zhou L, Huang Y, Wu S, Cheng X. Jiang W, et al. Front Genet. 2022 Jun 8;13:873230. doi: 10.3389/fgene.2022.873230. eCollection 2022. Front Genet. 2022. PMID: 35754821 Free PMC article.
References
-
- US Department of Agriculture, US Department of Health and Human Services. Report of the dietary guidelines advisory committee on the dietary guidelines for americans. 2010:24–26
-
- Hite AH, Feinman RD, Guzman GE, Satin M, Schoenfeld PA, Wood RJ. In the face of contradictory evidence: Report of the dietary guidelines for americans committee. Nutrition. 2010;26:915–924 - PubMed
-
- Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, et al. Omega-6 fatty acids and risk for cardiovascular disease: A science advisory from the american heart association nutrition subcommittee of the council on nutrition, physical activity, and metabolism; council on cardiovascular nursing; and council on epidemiology and prevention. Circulation. 2009;119:902–907 - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- UH3 NS100605/NS/NINDS NIH HHS/United States
- R01 NS017950/NS/NINDS NIH HHS/United States
- R01 AG054076/AG/NIA NIH HHS/United States
- N01 HC025195/HC/NHLBI NIH HHS/United States
- R01 AG008122/AG/NIA NIH HHS/United States
- R01 AG033193/AG/NIA NIH HHS/United States
- HHSN268201500001I/HL/NHLBI NIH HHS/United States
- U01 AG052409/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- U01 AG049505/AG/NIA NIH HHS/United States
- UH2 NS100605/NS/NINDS NIH HHS/United States
- N01HC25195/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous